IP26: Prostate Cancer: Localized: Ablative Therapy I
Saturday, May 16, 2026 7:00 AM to 9:00 AM · 2 hr. (America/New_York)
146A
Poster and Podium Sessions
Oncology: Prostate
Saturday, May 16
IP26-01: Comparison of Pathologic Characteristics and Salvage Treatment Between MRI Visible and Invisible Clinically Significant Prostate Cancer Recurrences (CSPCaR) Following Primary Partial Gland Cryo-ablation (PPGCA).
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-02: Tumor characteristics of in-field and out-of-field recurrences following focal therapy for localized prostate cancer: An analysis of 1050 patients
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-03: In-depth Spatial Pathologic Analysis of Infield Recurrences after focal High-Intensity Focused Ultrasound – Insights to improve cancer eradication
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-04: A multicenter evaluation of infield recurrence rates in patients treated with focal HIFU or cryotherapy
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-05: How to reduce the local recurrence rate of prostate cancer after focal HIFU?
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-06: Deep learning derived features from pre-treatment MRI predict failure of high intensity focused ultrasound (HIFU) therapy in prostate cancer patients.
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
Sumedh Sonawane
IP26-07: 5-Year Oncologic Outcomes and Predictive Factors After HIFU Treatment for Localized Prostate Cancer
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-08: MRI after HIFU Treatment is not a Reliable Determinant for Clinically Significant Prostate Cancer
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-09: Validation of existing risk stratification tools for predicting treatment failure after focal therapy: An analysis of 3460 patients from the HEAT and ICE registries
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-10: FOCS-24: A Composite Nomogram Predicting Complete Oncological and Functional Success after Focal Therapy for Localized Prostate Cancer
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
Umberto Anceschi · IRCSS "regina Elena" National Cancer Institute
IP26-11: 5-year outcomes after index lesion ablation of multifocal prostate cancer using focal HIFU and cryotherapy: An analysis of 1050 patients
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-12: Focal Therapy for Localised Prostate Cancer: Clinical and Imaging Predictors of Failure in a 4-Year Prospective Cohort
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-13: Impact of MRI-Detectable lesion Characteristics on Oncologic Outcomes after partial gland ablation for Localized Prostate Cancer
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-14: Pre-Treatment High-Risk Decipher Category Predicts Recurrence After Primary Focal Ablation
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-15: Success Metrics of Prostate Cancer Focal Therapy
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-16: Predictors of Salvage Radical Treatment After Partial Gland Focal Therapy for Localized Prostate Cancer
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-17: Determining Optimal Patient Selection for HIFU: Predictors of Treatment Failure
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-18: Does Incorporating Treatment Volume into Postoperative PSA Surveillance Following Prostate Cancer High Intensity Focused Ultrasound Therapy Improve the Predictive Performance for Recurrence?
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-19: Presence of Contralateral Clinically Significant Prostate Cancer in Radical Prostatectomy Specimens of Patients with Unilateral MRI Lesions and Its Influence on Eligibility for Focal Therapy
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-20: Transition Zone Sampling: A Simple Step That Prevents Errors in Focal Therapy Candidate Selection
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-21: Baseline Maximal Core and Total Length Gleason Pattern-4 Associated with Recurrence Risk after Primary Focal Ablation for Grade Group 2 Prostate Cancer in a Single Institution
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-22: Tumor–Capsule Contact Length on MRI as a Predictor of Oncologic Outcomes After Partial Gland Ablation for Prostate Cancer
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-23: Prognostic value of preoperative SUV in patients who underwent focal therapy HIFU: early prospective results from a single-center cohort
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-24: Single-tap versus double-tap high-intensity focused ultrasound (HIFU) for localized prostate cancer: a propensity score–matched analysis.
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-25: Intermediate to Long-term Outcomes of a Second Therapeutic Freeze following Primary Cryoablation: 7-year Median Follow-up
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-26: Lesion Location Impact on Early Cancer Outcomes and Sexual Functional Recovery After Focal Cryotherapy for Prostate Cancer
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-27: Impact of hemi-brachytherapy on prostate volume and sexual function in localized prostate cancer
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-28: Recovery of Potency after Primary Focal Therapy for Localized Prostate Cancer: A 2-Year Analysis by Modality
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-29: Re-thinking focal therapy: Whole gland ablation for patients with pre-existing sexual dysfunction
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
IP26-30: Microultrasound for Post-HIFU Surveillance in Localized Prostate Cancer: A Prospective Experience
Saturday, May 16, 2026 7:00 AM to 9:00 AM
146A
Registered attendees
Patrick Michael
FellowNCI/NIH